Castle Biosciences (CSTL) Expected to Release Quarterly Earnings on Thursday

Castle Biosciences (NASDAQ:CSTL) is anticipated to post its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect Castle Biosciences to post earnings of ($0.44) per share and revenue of $86.2360 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:30 PM ET.

Castle Biosciences (NASDAQ:CSTL) last announced its earnings results on Wednesday, May 6th. The company reported ($0.49) EPS for the quarter, meeting analysts’ consensus estimates of ($0.49). The company had revenue of $84.23 million during the quarter, compared to analysts’ expectations of $79.23 million. Castle Biosciences had a negative return on equity of 2.77% and a negative net margin of 3.78%. On average, analysts expect Castle Biosciences to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Castle Biosciences Stock Performance

NASDAQ CSTL opened at $24.81 on Thursday. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.75 and a quick ratio of 6.53. The company has a market cap of $752.49 million, a P/E ratio of -56.39 and a beta of 1.00. The stock has a 50-day moving average of $21.95 and a two-hundred day moving average of $27.13. Castle Biosciences has a 1-year low of $14.59 and a 1-year high of $44.28.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the stock. Wall Street Zen lowered shares of Castle Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Canaccord Genuity Group cut their target price on shares of Castle Biosciences from $50.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, April 20th. BTIG Research reduced their target price on shares of Castle Biosciences from $50.00 to $40.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th. Weiss Ratings cut shares of Castle Biosciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 1st. Finally, Robert W. Baird dropped their price target on shares of Castle Biosciences from $44.00 to $43.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Castle Biosciences currently has a consensus rating of “Moderate Buy” and an average target price of $42.43.

Insider Transactions at Castle Biosciences

In other news, insider Derek J. Maetzold sold 3,622 shares of Castle Biosciences stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $24.29, for a total value of $87,978.38. Following the completion of the transaction, the insider owned 12,368 shares in the company, valued at approximately $300,418.72. This trade represents a 22.65% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Kristen M. Oelschlager sold 8,586 shares of the business’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $24.42, for a total value of $209,670.12. Following the transaction, the chief operating officer directly owned 21,874 shares of the company’s stock, valued at approximately $534,163.08. This represents a 28.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 45,189 shares of company stock worth $1,014,561 in the last ninety days. 6.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Castle Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the company. Federated Hermes Inc. purchased a new stake in shares of Castle Biosciences during the 4th quarter worth $26,000. Kemnay Advisory Services Inc. purchased a new position in Castle Biosciences in the fourth quarter valued at $35,000. Jones Financial Companies Lllp increased its holdings in Castle Biosciences by 10,592.0% in the first quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock valued at $54,000 after buying an additional 2,648 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in Castle Biosciences by 256.9% in the second quarter. Tower Research Capital LLC TRC now owns 2,791 shares of the company’s stock valued at $57,000 after buying an additional 2,009 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its stake in Castle Biosciences by 63.7% in the third quarter. Russell Investments Group Ltd. now owns 2,508 shares of the company’s stock valued at $57,000 after buying an additional 976 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.